… More clinical trial data are needed to determine whether sera from COVID-19-convalescent
patients and neutralizing monoclonal antibodies specific to SARS-CoV-2 antigens can prevent …

… ) have focused on the development of neutralizing monoclonal antibodies (… neutralizing
activity, and protection provided by these nAbs play in the prevention and treatment of COVID-19 …

… is to develop those antibodies with a high affinity and avidity to treat COVID-19 by using …
to use the neutralizing antibodies for clinical application in the treatment of COVID-19. The …

… -CoV-2 neutralizing antibodies (nAbs) in the clinical management of COVID-19 and provide
… US Food and Drug Administration for the treatment of ambulatory patients who have a high …

… from mild COVID-19 demonstrated neutralizing antibody and S-binding antibody titres that
… vast majority of the SARS-CoV-2 neutralizing antibodies were not cross-reactive with SARS-…

… Coronavirus disease 2019 (COVID-19), … of antibodies in disease progression is unclear.
Given the ongoing development of treatment regimens for mild and severe cases of COVID-19, …

… the recent emergence of viral neutralizing antibody escape variants (3… neutralizing antibody
discovery efforts and review challenges for neutralizing antibody–based COVID-19 treatment …

… So far, many monoclonal antibodies are in the clinical trial phase, … neutralizing antibodies
and their role in combating Covid-19 … Antibodies provide a new hope to treat Covid-19 patients …

… analysis-of-covariance model with treatment group, risk factor, and baseline serum antibody
status as fixed effects and baseline viral load and treatment group–by–baseline viral load as …

… target of neutralizing antibodies (NAbs) and several neutralizing monoclonal antibodies (nMAbs…
In the absence of an effective treatment for COVID-19, passive immunization with nMAbs …